Clinical Research

Clinical Research

The doctors of Oncology Clinics Victoria have a long history of participation in clinical research. You may be asked to participate in a clinical trial, so talk to your doctor about the studies on offer.

Since commencing in 2003, over 90 clinical trials have been approved by the Ethics Committee. Over 700 patients have been enrolled, particularly in breast and colorectal cancer studies. 

We now have eight active principal investigators, a research manager, 7 study coordinators, 1 part time administrative assistant, and 1 Clinical Trials Pharmacist.

We participate in drug development trials.


Partner Organisations

Clinical Trials Australia
Monash Comprehensive Cancer Consortium 
American Association for Cancer Research
American Society of Clinical Oncology
Clinical Oncology Society of Australia
Medical Oncology Group of Australia
Private Cancer Physicians of Australia
Victorian Cooperative Oncology Group
Australasian Leukaemia and Lymphoma Study Group

Australian & New Zealand Breast Cancer Trials Group
International Association for the Study of Lung Cancer
Thoracic Society of Australia
Haematology Society of Australia
International Society of Gynaecologic Oncology
Australasian Gastro-Intestinal Trials Group 
Gynaecology Oncology Group - USA
Australian & New Zealand Gynaecological Oncology Group


Clinical Trials Australia

CTA is a not-for-profit organisation created to facilitate clinical trials in Medical Oncology in Australia. It is the preferred provider of early phase cancer clinical trials in the Asia-Pacific region. Oncology Clinics Victoria joins many other institutions including the Walter & Eliza Hall, Ludwig Institute, Peter MacCallum Cancer Institute, Royal Melbourne Hospital, Austin Hospital, Western Hospital, Alfred Hospital, Monash Medical Centre, St Vincent’s Hospital, and Frankston Hospital, to promote clinical research. 

CTA develops Phase I/II trials of molecular therapeutics with laboratory and functional imaging assessment of biomarkers, and Phase I, II and III clinical trials with cytokines, cytotoxic agents, immunological therapies and biological compounds. It allows our patients access to many new and exciting agents in the treatment of cancer.


Monash Comprehensive Cancer Consortium

Oncology Clinics Victoria, through Cabrini Health, is an inaugural partner with Monash University, Southern Melbourne Integrated Cancer Services, Southern Health, Alfred Heath, Monash Institute of Medical Research, Peninsula Health, and the Prince Henry’s Institute. The vision is to bring together the research and clinical strengths of these institutions to deliver an internationally recognised cancer research program that complements a world class system of integrated clinical cancer care in South-east Victoria.    

The Monash Comprehensive Cancer Consortium operates as one of the three major cancer nodes in Victoria’s integrated system of cancer research and care. MCCC will work collaboratively with the other two major centres – the Parkville Comprehensive Cancer Centre and the Olivia Newton John Cancer and Wellness Centre at the Austin Hospital, to interconnect research and clinical strengths in ways that maximize benefits for Victoria’s cancer patients.

MCCC makes a distinctive contribution in improving the outcomes for Victoria’s cancer patients by ensuring best possible clinical outcomes for the 30% of Victoria’s cancer patients resident in the south-east corridor, by integrating the consortium’s cancer research and workforce development programs with the clinical care initiatives of SMICS and the major health service providers in this region. Also by improving outcomes for patients in regional Southeast Victoria – by developing joint cancer research, workforce development and clinical trials programs across Gippsland and southern Melbourne; and improving quality of life for patients by integrating palliative and supportive care research with the consortium’s tumour stream programs

MCCC delivers significant outcomes, notably development of new therapeutics that move treatment outcomes beyond the limitations of current chemotherapy approaches, by specifically targeting the cancer stem cells that are believed to lead to remission and death. Also providing patients in south-east Victoria with access to leading-edge therapies, by undertaking world-first clinical trials of these new therapeutics in the partner hospitals.